Literature DB >> 6308033

beta-endorphin suppresses adrenocorticotropin and cortisol levels in normal human subjects.

T Taylor, R G Dluhy, G H Williams.   

Abstract

To determine the effect of beta-endorphin on the pituitary-adrenal axis, human synthetic beta-endorphin was infused iv in 10 normal human subjects. Either beta-endorphin (0.3, 1.0, and 3.0 micrograms/kg . min, each dose for 30 min) or a control (sham) infusion of 5% dextrose water was administered in a blind fashion in the same subjects on 2 successive days. Plasma ACTH and cortisol and serum human GH and PRL levels were measured 30 min before and then every 30 min for 210 min during and after both the beta-endorphin and control infusions. In all subjects, cortisol levels decreased below the basal level in response to the infusion of beta-endorphin. The threshold dose was 1.0 micrograms/kg . min, with the mean control cortisol level (12 +/- 2 micrograms/dl) declining significantly to 7 +/- 1 micrograms/dl (1.0 micrograms/kg . min) and 6 +/- 1 micrograms/dl (3.0 micrograms/kg . min; P less than 0.01). ACTH levels also were significantly lower than the control value (48 +/- 6 pg/ml) at the 1.0 microgram/kg . min dose (32 +/- 4 pg/ml; P less than 0.05). The decline in ACTH and cortisol levels was also significantly different from levels obtained during the control infusions (P = 0.001 and P = 0.01, respectively). The results are consistent with short feedback loop inhibition of pituitary ACTH release or suppression of hypothalamic corticotropin-releasing factor release by beta-endorphin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6308033     DOI: 10.1210/jcem-57-3-592

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  The genetic dissection of complex traits in a founder population.

Authors:  C Ober; M Abney; M S McPeek
Journal:  Am J Hum Genet       Date:  2001-10-03       Impact factor: 11.025

2.  Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene.

Authors:  Eliza B Geer; Rita E Landman; Sharon L Wardlaw; Irene M Conwell; Pamela U Freda
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Potentiation of the hCRF-induced release of ACTH in man by an opioid antagonist.

Authors:  H Ehrenreich; C Kolmar; O A Müller; F D Goebel
Journal:  Klin Wochenschr       Date:  1987-05-15

Review 4.  Changes in beta-endorphin levels in response to aerobic and anaerobic exercise.

Authors:  L Schwarz; W Kindermann
Journal:  Sports Med       Date:  1992-01       Impact factor: 11.136

Review 5.  POMC: The Physiological Power of Hormone Processing.

Authors:  Erika Harno; Thanuja Gali Ramamoorthy; Anthony P Coll; Anne White
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

6.  Multiple feedback regulatory loops upon rat hypothalamic corticotropin-releasing hormone secretion. Potential clinical implications.

Authors:  A E Calogero; W T Gallucci; P W Gold; G P Chrousos
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

7.  Increased glucocorticoid receptor expression and activity mediate the LPS resistance of SPRET/EI mice.

Authors:  Lien Dejager; Iris Pinheiro; Leen Puimège; Ye-Dong Fan; Lies Gremeaux; Hugo Vankelecom; Claude Libert
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

8.  Effects of naloxone on prolactin, growth hormone and cortisol response to insulin hypoglycemia in obese subjects.

Authors:  D Papalia; M Lunetta; M Di Mauro
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

9.  Effect of naltrexone treatment on the treadmill exercise-induced hormone release in amenorrheic women.

Authors:  G Botticelli; A Bacchi Modena; D Bresciani; P Villa; L Aguzzoli; P Florio; R E Nappi; F Petraglia; A R Genazzani
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

Review 10.  From Pharmacology to Physiology: Endocrine Functions of μ-Opioid Receptor Networks.

Authors:  Nikolai Jaschke; Sophie Pählig; Ying-Xian Pan; Lorenz C Hofbauer; Andy Göbel; Tilman D Rachner
Journal:  Trends Endocrinol Metab       Date:  2021-03-03       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.